← Back to News

Sitryx strengthens early clinical capability with the appointment of Lisa Pierre.

17th March 2023

Oxford, UK – 17 March 2023 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation and immuno-oncology, today announces the appointment of Lisa Pierre, Ph.D., as Head of Early Clinical Development.

Lisa brings 20 years of strategic and scientific expertise across early clinical development. At Sitryx, Lisa will join the Company’s senior management team where she will help lead the Company’s progress towards the clinic as Sitryx advances its pipeline of disease-modifying therapeutics in immuno-inflammation and immuno-oncology.

Iain Kilty, Chief Scientific Officer of Sitryx, said: “We are delighted to welcome Lisa to the Sitryx team. Her wealth of strategic experience supporting biotechnology and biopharmaceutical companies to progress their programmes through early clinical development is a key addition to the leadership team. Lisa joins us at an exciting time as we become a clinical stage company and bring our immunometabolism targeting therapies to patients in need.”

Lisa Pierre said: “Sitryx is establishing itself as a leader in the field of immunometabolism, building a diverse pipeline of potentially first in class therapies in immuno-inflammation and metabolism. I am very excited to join the team and look forward to working together as we move towards the clinic to deliver important, novel therapies to patients.”

Lisa joins Sitryx from the Lung Cancer Initiative at Johnson and Johnson where, as Senior Director, she was responsible for driving the strategic and scientific direction of cross-sector (Pharm and MedTech), multidisciplinary development teams focused on the interception and treatment of lung cancer. Her previous roles include Senior Director, Clinical Development and Project Leader at RespiVert, a small, inhaled medicines company successfully delivering early clinical projects focused on treatments for respiratory diseases such as COPD and severe asthma, Early Development Lead in Immunology Translational Medicine at Janssen and Director of Clinical Research at the Merck Translational Medicines Research Centre in Singapore. Prior to that Lisa spent 10 years in roles of increasing responsibility at GlaxoSmithKline within Clinical Pharmacology and Discovery Medicine specialising in respiratory diseases.

Lisa holds a first class honours degree in Pharmacology from King’s College, London and a Ph.D. in Pharmacology from University of Cambridge, UK.

For more information about Sitryx, visit www.sitryx.com

About Sitryx

Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field of immunology and metabolism; Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak. Together they have published more than 1,000 papers in the field, making multiple key breakthroughs in our understanding of how critical energetic status is to the behavior of immune cells and in the broader field of immunology. In 2018, Sitryx raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2020, Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the Company. The Company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK. For more information, please visit www.sitryx.com.